Shaji Kumar1. 1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. kumar.shaji@mayo.edu
Abstract
PURPOSE OF REVIEW: Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role of SCT for its management. This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies. RECENT FINDINGS: Recent clinical trials have primarily focused on improving patient outcome by integrating the novel agents into various stages of myeloma therapy, including initial therapy resulting in improvement of disease control at the time of SCT, incorporation into conditioning regimens and finally, using maintenance approaches to prolong the response from SCT. In addition, recent trials also have demonstrated a potential role for tandem SCT in selected patients. However, the role of allogeneic SCT still remains to be better defined. SUMMARY: Patients with myeloma have more effective choices for therapy today and better outcome. Recent and ongoing trials will allow better selection of therapy, preferably in an individualized fashion, potentially translating into prolonged survival.
PURPOSE OF REVIEW: Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role of SCT for its management. This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies. RECENT FINDINGS: Recent clinical trials have primarily focused on improving patient outcome by integrating the novel agents into various stages of myeloma therapy, including initial therapy resulting in improvement of disease control at the time of SCT, incorporation into conditioning regimens and finally, using maintenance approaches to prolong the response from SCT. In addition, recent trials also have demonstrated a potential role for tandem SCT in selected patients. However, the role of allogeneic SCT still remains to be better defined. SUMMARY:Patients with myeloma have more effective choices for therapy today and better outcome. Recent and ongoing trials will allow better selection of therapy, preferably in an individualized fashion, potentially translating into prolonged survival.
Authors: A Keith Stewart; Christine I Chen; Kang Howson-Jan; Darrell White; Jean Roy; Michael J Kovacs; Chaim Shustik; Anna Sadura; Lois Shepherd; Keyue Ding; Ralph M Meyer; Andrew R Belch Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: S K Kumar; D Dingli; A Dispenzieri; M Q Lacy; S R Hayman; F K Buadi; S V Rajkumar; M R Litzow; M A Gertz Journal: Bone Marrow Transplant Date: 2008-03-10 Impact factor: 5.483
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: M A Gertz; M Q Lacy; A Dispenzieri; S R Hayman; S Kumar; N Leung; D A Gastineau Journal: Bone Marrow Transplant Date: 2007-03-19 Impact factor: 5.483
Authors: John Kuruvilla; John D Shepherd; Heather J Sutherland; Thomas J Nevill; Janet Nitta; Aulan Le; Donna L Forrest; Donna E Hogge; Julye C Lavoie; Stephen H Nantel; Cynthia L Toze; Clayton A Smith; Micheal J Barnett; Kevín W Song Journal: Biol Blood Marrow Transplant Date: 2007-05-29 Impact factor: 5.742
Authors: Edward A Stadtmauer; Keith M Sullivan; Francisco M Marty; Sanjeet S Dadwal; Genovefa A Papanicolaou; Thomas C Shea; Sherif B Mossad; Charalambos Andreadis; Jo-Anne H Young; Francis K Buadi; Mohamed El Idrissi; Thomas C Heineman; Elchonon M Berkowitz Journal: Blood Date: 2014-09-18 Impact factor: 22.113
Authors: Wilson I Gonsalves; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Yi Lin; Preet P Singh; Vinay Gupta; Suzanne R Hayman; Francis K Buadi; David Dingli; Prashant Kapoor; Arleigh R McCurdy; Shaji K Kumar Journal: Blood Date: 2013-07-17 Impact factor: 22.113